Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATRA Atara Biotherapeutics	$9.23 -0.4%	$7.87	$5.01 ▼ $18.71	$55.26M	0.18	117,699 shs	35,334 shs
BVNRY Bavarian Nordic	$9.12 +1.4%	$8.67	$6.60 ▼ $14.60	$2.13B	1.36	2,676 shs	8,417 shs
KRYS Krystal Biotech	$148.90 +3.9%	$136.50	$122.80 ▼ $219.34	$4.14B	0.67	286,959 shs	538,250 shs
MESO Mesoblast	$10.51 +0.6%	$11.24	$5.78 ▼ $22.00	$1.34B	2.39	277,225 shs	174,166 shs
RCEL Avita Medical	$5.63 +0.4%	$6.27	$4.71 ▼ $14.16	$148.30M	1.52	189,391 shs	356,160 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATRA Atara Biotherapeutics	-0.43%	+11.88%	-0.32%	+74.15%	+13.95%
BVNRY Bavarian Nordic	+1.39%	+3.28%	-0.38%	+27.20%	+1.79%
KRYS Krystal Biotech	+3.88%	+5.34%	+9.42%	-7.31%	-23.09%
MESO Mesoblast	+0.57%	-3.22%	-11.31%	+1.06%	+38.38%
RCEL Avita Medical	+0.36%	+8.90%	-7.86%	-34.76%	-33.69%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATRA Atara Biotherapeutics	4.0946 of 5 stars	3.3	3.0	0.0	4.7	0.6	2.5	0.6
BVNRY Bavarian Nordic	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KRYS Krystal Biotech	4.491 of 5 stars	3.5	1.0	0.0	4.7	2.2	2.5	1.9
MESO Mesoblast	1.9434 of 5 stars	3.5	1.0	0.0	0.0	2.4	0.8	0.6
RCEL Avita Medical	0.8502 of 5 stars	3.4	0.0	0.0	0.0	0.0	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATRA Atara Biotherapeutics	2.57	Moderate Buy	$17.75	92.31% Upside
BVNRY Bavarian Nordic	0.00	N/A	N/A	N/A
KRYS Krystal Biotech	3.00	Buy	$211.13	41.79% Upside
MESO Mesoblast	3.00	Buy	$18.00	71.27% Upside
RCEL Avita Medical	2.75	Moderate Buy	$16.50	193.07% Upside

Current Analyst Ratings Breakdown

Latest ATRA, RCEL, BVNRY, MESO, and KRYS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/9/2025	KRYS Krystal Biotech	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
6/24/2025	KRYS Krystal Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$240.00
6/6/2025	RCEL Avita Medical	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$19.00
5/16/2025	KRYS Krystal Biotech	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$215.00 ➝ $155.00
5/7/2025	KRYS Krystal Biotech	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$195.00 ➝ $189.00
5/7/2025	KRYS Krystal Biotech	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$219.00 ➝ $219.00
5/6/2025	KRYS Krystal Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$240.00 ➝ $240.00
4/28/2025	KRYS Krystal Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$221.00 ➝ $240.00
4/10/2025	RCEL Avita Medical	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00 ➝ $22.00

(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATRA Atara Biotherapeutics	$128.94M	0.43	N/A	N/A	($16.89) per share	-0.55
BVNRY Bavarian Nordic	$829.12M	2.60	$1.03 per share	8.88	$6.99 per share	1.30
KRYS Krystal Biotech	$290.52M	14.81	$4.82 per share	30.91	$32.90 per share	4.53
MESO Mesoblast	$5.90M	227.62	N/A	N/A	$4.21 per share	2.50
RCEL Avita Medical	$71.66M	2.08	N/A	N/A	$0.17 per share	33.12

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATRA Atara Biotherapeutics	-$85.40M	-$3.72	N/A	N/A	N/A	-7.83%	N/A	-14.51%	8/11/2025 (Estimated)
BVNRY Bavarian Nordic	$143.26M	$0.80	11.40	8.69	N/A	21.11%	11.89%	9.32%	8/28/2025 (Estimated)
KRYS Krystal Biotech	$89.16M	$4.16	35.79	14.77	N/A	37.17%	14.64%	13.28%	8/4/2025 (Estimated)
MESO Mesoblast	-$87.96M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/29/2025 (Estimated)
RCEL Avita Medical	-$61.85M	-$2.19	N/A	N/A	N/A	-79.61%	-632.62%	-71.72%	8/6/2025 (Estimated)

Latest ATRA, RCEL, BVNRY, MESO, and KRYS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/4/2025	Q2 2025	KRYS Krystal Biotech	$1.20	N/A	N/A	N/A	$95.42 million	N/A
5/15/2025	Q1 2025	ATRA Atara Biotherapeutics	-$3.07	$3.50	+$6.57	$3.50	$4.30 million	$98.10 million
5/9/2025	Q1 2025	BVNRY Bavarian Nordic	N/A	$0.13	N/A	$0.13	N/A	$189.89 million
5/8/2025	Q1 2025	RCEL Avita Medical	-$0.39	-$0.53	-$0.14	-$0.53	$33.15 million	$18.51 million
5/6/2025	Q1 2025	KRYS Krystal Biotech	$1.38	$1.20	-$0.18	$1.20	$98.66 million	$88.18 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATRA Atara Biotherapeutics	N/A	N/A	N/A	N/A	N/A
BVNRY Bavarian Nordic	N/A	N/A	N/A	N/A	N/A
KRYS Krystal Biotech	N/A	N/A	N/A	N/A	N/A
MESO Mesoblast	N/A	N/A	N/A	N/A	N/A
RCEL Avita Medical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATRA Atara Biotherapeutics	N/A	0.57	0.57
BVNRY Bavarian Nordic	N/A	2.81	1.44
KRYS Krystal Biotech	N/A	9.65	9.27
MESO Mesoblast	0.22	0.96	0.63
RCEL Avita Medical	9.39	2.09	1.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATRA Atara Biotherapeutics	70.90%
BVNRY Bavarian Nordic	N/A
KRYS Krystal Biotech	86.29%
MESO Mesoblast	1.43%
RCEL Avita Medical	27.66%

Insider Ownership

Company	Insider Ownership
ATRA Atara Biotherapeutics	4.00%
BVNRY Bavarian Nordic	N/A
KRYS Krystal Biotech	13.70%
MESO Mesoblast	18.80%
RCEL Avita Medical	2.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATRA Atara Biotherapeutics	330	5.96 million	5.72 million	Optionable
BVNRY Bavarian Nordic	1,611	236.57 million	N/A	Not Optionable
KRYS Krystal Biotech	210	28.90 million	24.94 million	Optionable
MESO Mesoblast	80	127.78 million	103.76 million	Optionable
RCEL Avita Medical	130	26.44 million	25.70 million	Optionable

ATRA, RCEL, BVNRY, MESO, and KRYS Headlines

Recent News About These Companies

Avita Medical Ltd (RCEL) Stock Forums - Investing.com

June 30, 2025 | investing.com

AVITA Medical, Inc. (RCEL) - Yahoo Finance

June 27, 2025 | finance.yahoo.com

Analysts Expect Breakeven For AVITA Medical, Inc. (NASDAQ:RCEL) Before Long

June 21, 2025 | finance.yahoo.com

Cantor Fitzgerald Predicts AVITA Medical FY2026 Earnings

June 11, 2025 | marketbeat.com

AVITA Medical Announces First Clinical Publication Demonstrating Accelerated Autograft Readiness with Cohealyx™

June 5, 2025 | finance.yahoo.com

AVITA Medical's RECELL Platform Recognized for Surgical Innovation in 2025 MedTech Breakthrough Awards

June 3, 2025 | globenewswire.com

AVITA Medical’s Acute Wound Care Showcase 2025 Streams Live Today

May 13, 2025 | finance.yahoo.com

AVITA Medical: Near-Perfect Execution Needed To Navigate Through Balance Sheet Challenges

May 12, 2025 | seekingalpha.com

Analysts Have Been Trimming Their AVITA Medical, Inc. (NASDAQ:RCEL) Price Target After Its Latest Report

May 11, 2025 | finance.yahoo.com

AVITA Medical, Inc. (RCEL) Q1 2025 Earnings Call Transcript

May 8, 2025 | seekingalpha.com

AVITA Medical Reports First Quarter 2025 Financial Results

May 8, 2025 | globenewswire.com

AVITA Medical to Announce First Quarter 2025 Financial Results

April 17, 2025 | globenewswire.com

AVITA Medical to Present Breakthrough Clinical Data in Burn and Wound Care at ABA 2025

April 9, 2025 | globenewswire.com

6 Analysts Assess AVITA Medical: What You Need To Know

April 6, 2025 | nasdaq.com

Avita Medical announces U.S. commercial launch of Cohealyx

April 4, 2025 | msn.com

AVITA Medical Launches Cohealyx, Supporting Healing and Unlocking New Market Opportunity

April 3, 2025 | globenewswire.com

AVITA Medical’s SWOT analysis: regenerative medicine stock faces growth hurdles

March 21, 2025 | uk.investing.com

4RCEL : What Analysts Are Saying About AVITA Medical Stock

March 18, 2025 | benzinga.com

Avita Medical amends PermeaDerm distribution agreement with Stedical Scientific

March 17, 2025 | markets.businessinsider.com

Avita Medical Boosts Production with New Agreement

March 17, 2025 | tipranks.com

AVITA Medical Announces Exclusive Manufacturing and Distribution Agreements with Stedical Scientific

March 17, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
UPS Is Outpacing the Market: A Green Light for Investors?
By Jeffrey Neal Johnson | June 27, 2025
View UPS Is Outpacing the Market: A Green Light for Investors?

ATRA, RCEL, BVNRY, MESO, and KRYS Company Descriptions

Atara Biotherapeutics NASDAQ:ATRA

$9.23 -0.04 (-0.43%)

Closing price 07/9/2025 04:00 PM Eastern

Extended Trading

$9.07 -0.16 (-1.68%)

As of 07/9/2025 07:56 PM Eastern

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Bavarian Nordic OTCMKTS:BVNRY

$9.12 +0.13 (+1.39%)

As of 07/9/2025 11:46 AM Eastern

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2. The company has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. It operates in the United States, Canada, France, Germany, Spain, Australia, Switzerland, Sweden, Chile, Taiwan, the United Kingdom, Hong Kong, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

Krystal Biotech NASDAQ:KRYS

$148.90 +5.56 (+3.88%)

Closing price 07/9/2025 04:00 PM Eastern

Extended Trading

$148.92 +0.01 (+0.01%)

As of 05:04 AM Eastern

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Mesoblast NASDAQ:MESO

$10.51 +0.06 (+0.57%)

Closing price 07/9/2025 04:00 PM Eastern

Extended Trading

$10.58 +0.08 (+0.71%)

As of 07/9/2025 05:29 PM Eastern

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Avita Medical NASDAQ:RCEL

$5.63 +0.02 (+0.36%)

Closing price 07/9/2025 04:00 PM Eastern

Extended Trading

$5.62 0.00 (-0.09%)

As of 04:36 AM Eastern

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time